The company raised the midpoint of its full-year adjusted EPS outlook and now expects earnings of $12.62 to $12.72 per share. BD cited double-digit growth in biologic drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration. Connected Care revenue rose 4.4%, led by double-digit growth in advanced patient monitoring and continued strength in consumables. Updated Outlook and 2027 ConsiderationsBD now expects fiscal 2026 revenue growth toward the high end of its low-single-digit FX-neutral range. About Becton, Dickinson and Company (NYSE:BDX)Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents.